Senti Biosciences Holdings, Inc. SNTI
2.79 USD -0.08 (-2.82%)
Regular-session close
2.79 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
2.50 Day range 3.02
2.79 52-week range 2.79
- YTD
- 0.00%
- 1 year
- 0.00%
News
defenseworld.net Reviewing Senti Biosciences (NASDAQ:SNTI) and Xenon Pharmaceuticals (NASDAQ:XENE) Senti Biosciences (NASDAQ: SNTI - Get Free Report) and Xenon Pharmaceuticals (NASDAQ: XENE - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the…
globenewswire.com Senti Bio Announces Reverse Stock Split SOUTH SAN FRANCISCO, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene…
defenseworld.net Rhythm Pharmaceuticals (NASDAQ:RYTM) & Senti Biosciences (NASDAQ:SNTI) Head to Head Survey Senti Biosciences (NASDAQ: SNTI - Get Free Report) and Rhythm Pharmaceuticals (NASDAQ: RYTM - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the…benzinga.com Senti Biosciences Enters Equity Commitment Letter With CPIF II-9 On Nov 9, 2026; CPIF II-9 To Purchase Up To $4.55M Of Senti Biosciences Common Stock On November 9, 2026, Senti Biosciences Holdings, Inc., a Delaware corporation (the "Company"), entered into a new equity commitment letter (the "Equity Commitment Letter"), with CPIF II-9 Limited, an
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…
benzinga.com Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket Celestica jumps 16.4% after beating Q3 FY26 estimates and raising guidance; 22nd Century leads premarket gainers at 69.8%.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Senti Biosciences (NASDAQ:SNTI) stock rose 51.8% to $0.27 during Monday's after-market session. The company's market cap stands at $5.9 million. Polyrizon (NASDAQ:PLRZ) shares increased by…
defenseworld.net Head-To-Head Analysis: Senti Biosciences (NASDAQ:SNTI) and Celldex Therapeutics (NASDAQ:CLDX) Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Senti Biosciences (NASDAQ: SNTI - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two…
defenseworld.net Senti Biosciences (SNTI) to Announce Quarterly Earnings on Thursday Senti Biosciences (NASDAQ: SNTI - Get Free Report) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.33)…
globenewswire.com Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) (“SBH” or the “Company”) today announced a strategic transaction designed to sharpen its…
globenewswire.com Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory…
globenewswire.com Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep…
globenewswire.com Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene…
globenewswire.com Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies SOUTH SAN FRANCISCO, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene…
globenewswire.com Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene…
defenseworld.net Senti Biosciences, Inc. (NASDAQ:SNTI) Given Average Rating of “Moderate Buy” by Brokerages Shares of Senti Biosciences, Inc. (NASDAQ: SNTI - Get Free Report) have received an average rating of "Moderate Buy" from the five brokerages that are presently covering the firm, MarketBeat reports.…
globenewswire.com Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene…
globenewswire.com Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene…
defenseworld.net Senti Biosciences, Inc. (NASDAQ:SNTI) Given Consensus Recommendation of “Moderate Buy” by Analysts Senti Biosciences, Inc. (NASDAQ: SNTI - Get Free Report) has been given an average rating of "Moderate Buy" by the five brokerages that are presently covering the stock, Marketbeat reports. One…
globenewswire.com Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene…
globenewswire.com Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene…
globenewswire.com Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202…
globenewswire.com Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026 SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene…
globenewswire.com Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation Access the segment here
